FIELD: medicine.
SUBSTANCE: invention relates to experimental medicine, and can be used for protection of post-vaccination immunity to tetanus anatoxin against methotrexate-induced depression. Method includes parenteral introduction of miliacin into experimental animal organism in dose 2 mg/kg of weight. Miliacin is introduced tree times daily to animals with formed post-vaccination immunity to tetanus anatoxin, subjected to immunodepressive impact of methotrexate cytostatic.
EFFECT: application of invention allows to protect formed post-vaccination immunity against immunodepressive impact of cytostatic due to anticatabolic action of miliacin.
5 dwg
| Title | Year | Author | Number | 
|---|---|---|---|
| AGENT ENHANCING IMMUNOGENIC PROPERTY OF TETANUS ANATOXIN | 2003 | 
 | RU2244548C1 | 
| MEDICATION INCREASING ANTITUMOUR EFFECT OF METHOTREXATE | 2009 | 
 | RU2411947C1 | 
| AGENT LIMITING LYMPHOTOXIN EFFECT OF METHOTREXATE | 2007 | 
 | RU2337693C1 | 
| AGENT FOR REDUCING SYSTEMIC PATHOLOGIC ENDOTOXINEMIA | 2014 | 
 | RU2564918C1 | 
| ANTIMUTAGENIC AGENT | 2019 | 
 | RU2698204C1 | 
| METHOD FOR REDUCING GEMOTOXIC ACTION OF BENZENE ON AN ORGANISM | 2017 | 
 | RU2724891C2 | 
| AGENT WITH IMMUNOPOTENTIATING ACTIVITY | 2007 | 
 | RU2347562C2 | 
| METHOD FOR IMMUNIZATION IN PREGNANT COWS FOR PREVENTING VIRAL DIARRHEA AS MUCOSAL DISEASE IN CALVES | 2002 | 
 | RU2212892C1 | 
| AGENT OF IMMUNOMODULATING ACTIVITY | 2007 | 
 | RU2329821C1 | 
| AGENT OF IMMUNOMODULATING ACTIVITY | 2007 | 
 | RU2337700C1 | 
Authors
Dates
2010-07-20—Published
2008-12-25—Filed